Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage III Malignant Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06075524
What this trial is testing

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Lung Carcinoma+7 more
Mayo Clinic 500
Testing effectiveness (Phase 2)Study completedNCT01189383
What this trial is testing

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Who this might be right for
Malignant Melanoma Stage IIIMalignant Melanoma Stage IV
Baylor Research Institute 20
Early research (Phase 1)Study completedNCT00085488
What this trial is testing

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Melanoma (Skin)
Dartmouth-Hitchcock Medical Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT05289193
What this trial is testing

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Who this might be right for
MelanomaMelanoma Stage III
Memorial Sloan Kettering Cancer Center 28
Large-scale testing (Phase 3)Active Not RecruitingNCT05270044
What this trial is testing

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Who this might be right for
Melanoma
Pierre Fabre Medicament 815
Not applicableStudy completedNCT03493230
What this trial is testing

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )

Who this might be right for
Malignant Melanoma Stage IVMalignant Melanoma Stage III
Centre Hospitalier Universitaire de Nice 35
Testing effectiveness (Phase 2)Ended earlyNCT00184067
What this trial is testing

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

Who this might be right for
Melanoma
University of Southern California 23
Large-scale testing (Phase 3)Study completedNCT00111007
What this trial is testing

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
Bayer 270
Testing effectiveness (Phase 2)Ended earlyNCT02303951
What this trial is testing

Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC

Who this might be right for
Malignant Melanoma
University Hospital Tuebingen 47
Not applicableStudy completedNCT04680182
What this trial is testing

Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients

Who this might be right for
MelanomaComplication
Oslo University Hospital 104
Large-scale testing (Phase 3)Ended earlyNCT00087776
What this trial is testing

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

Who this might be right for
Malignant Melanoma
American Regent, Inc. 393
Early research (Phase 1)WithdrawnNCT01843738
What this trial is testing

Radiation Use During Vemurafenib Treatment

Who this might be right for
BRAFV600 MutationStage IV Melanoma
University of Utah
Large-scale testing (Phase 3)Active Not RecruitingNCT05078047
What this trial is testing

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Who this might be right for
Lung Cancer MetastaticRenal Cell CarcinomaHead and Neck Cancer+12 more
UNICANCER 646
Testing effectiveness (Phase 2)Study completedNCT00135408
What this trial is testing

MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Who this might be right for
Malignant Melanoma
Bristol-Myers Squibb 115
Large-scale testing (Phase 3)Study completedNCT02388906
What this trial is testing

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 906
Not applicableEnrolling By InvitationNCT06605833
What this trial is testing

CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma

Who this might be right for
Melanoma Stage III or IV
Royal Marsden NHS Foundation Trust 60
Not applicableLooking for participantsNCT06784778
What this trial is testing

Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.

Who this might be right for
Melanoma MetastaticMelanoma, SkinMelanoma Stage III or IV+1 more
Pamgene International B.V. 196
Early research (Phase 1)Study completedNCT00030615
What this trial is testing

Decitabine in Treating Patients With Advanced Solid Tumors

Who this might be right for
Male Breast CancerRecurrent Bladder CancerRecurrent Breast Cancer+6 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Ended earlyNCT06984328
What this trial is testing

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Who this might be right for
Cutaneous MelanomaRelapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV)
Genmab 1
Testing effectiveness (Phase 2)Ended earlyNCT02587650
What this trial is testing

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Who this might be right for
ALK Fusion Protein ExpressionBRAF wt AlleleInvasive Skin Melanoma+12 more
University of California, San Francisco 1
Next Page